1 School of Pharmacy and.
2 Keck School of Medicine, University of Southern California, Los Angeles, California; and.
Am J Respir Cell Mol Biol. 2018 Mar;58(3):310-319. doi: 10.1165/rcmb.2016-0428OC.
Acute lung injury (ALI) is a clinical syndrome characterized by acute respiratory failure and is associated with substantial morbidity and mortality. Rhesus θ-defensin (RTD)-1 is an antimicrobial peptide with immunomodulatory activity. As airway inflammation and neutrophil recruitment and activation are hallmarks of ALI, we evaluated the therapeutic efficacy of RTD-1 in preclinical models of the disease. We investigated the effect of RTD-1 on neutrophil chemotaxis and macrophage-driven pulmonary inflammation with human peripheral neutrophils and LPS-stimulated murine alveolar macrophage (denoted MH-S) cells. Treatment and prophylactic single escalating doses were administered subcutaneously in a well-established murine model of direct endotoxin-induced ALI. We assessed lung injury by histopathology, pulmonary edema, inflammatory cell recruitment, and inflammatory cytokines/chemokines in the BAL fluid. In vitro studies demonstrated that RTD-1 suppressed CXCL8-induced neutrophil chemotaxis, TNF-mediated neutrophil-endothelial cell adhesion, and proinflammatory cytokine release in activated murine alveolar immortalized macrophages (MH-S) cells. Treatment with RTD-1 significantly inhibited in vivo LPS-induced ALI by reducing pulmonary edema and histopathological changes. Treatment was associated with dose- and time-dependent inhibition of proinflammatory cytokines (TNF, IL-1β, and IL-6), peroxidase activity, and neutrophil recruitment into the airways. Antiinflammatory effects were demonstrated in animals receiving RTD-1 up to 12 hours after LPS challenge. Notably, subcutaneously administered RTD-1 demonstrates good peptide stability as demonstrated by the long in vivo half-life. Taken together, these studies demonstrate that RTD-1 is efficacious in an experimental model of ALI through inhibition of neutrophil chemotaxis and adhesion, and the attenuation of proinflammatory cytokines and gene expression from alveolar macrophages.
急性肺损伤(ALI)是一种以急性呼吸衰竭为特征的临床综合征,与较高的发病率和死亡率相关。恒河猴θ防御素(RTD)-1 是一种具有免疫调节活性的抗菌肽。由于气道炎症、中性粒细胞募集和激活是 ALI 的标志,我们评估了 RTD-1 在疾病的临床前模型中的治疗效果。我们用人类外周血中性粒细胞和 LPS 刺激的鼠肺泡巨噬细胞(命名为 MH-S 细胞)研究了 RTD-1 对中性粒细胞趋化和巨噬细胞驱动的肺部炎症的影响。在一个成熟的直接内毒素诱导的 ALI 鼠模型中,我们通过皮下给药来治疗和预防单递增剂量。我们通过组织病理学、肺水肿、炎症细胞募集以及 BAL 液中的炎症细胞因子/趋化因子来评估肺损伤。体外研究表明,RTD-1 抑制了 CXCL8 诱导的中性粒细胞趋化、TNF 介导的中性粒细胞-内皮细胞粘附以及激活的鼠肺泡永生化巨噬细胞(MH-S)细胞中的促炎细胞因子释放。RTD-1 治疗显著抑制了 LPS 诱导的体内 ALI,减少了肺水肿和组织病理学变化。治疗与剂量和时间依赖性地抑制促炎细胞因子(TNF、IL-1β 和 IL-6)、过氧化物酶活性和中性粒细胞向气道募集有关。在 LPS 攻击后 12 小时内接受 RTD-1 治疗的动物中观察到抗炎作用。值得注意的是,皮下给予的 RTD-1 表现出良好的肽稳定性,体内半衰期长。综上所述,这些研究表明,RTD-1 通过抑制中性粒细胞趋化和粘附以及减弱肺泡巨噬细胞中的促炎细胞因子和基因表达,在 ALI 的实验模型中是有效的。